ANEB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANEB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Anebulo Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate is N/A.
For the Biotechnology subindustry, Anebulo Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Anebulo Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate falls into.
Anebulo Pharmaceuticals (NAS:ANEB) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Bimal R. Shah | director | C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052 |
Richard Anthony Cunningham, | director, officer: Chief Executive Officer | ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139 |
Dan George | officer: Chief Financial Officer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Sandra A. Gardiner | officer: Acting Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kenneth C Cundy | officer: Chief Scientific Officer | 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025 |
Nathaniel Calloway | director | C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734 |
Simon Allen | director, officer: Chief Executive Officer | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Aron R. English | director, 10 percent owner | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Kenneth Lin | director | PO BOX 1005, LOS ALTOS CA 94022 |
Karah Herdman Parschauer | director | 60 LEVERONI COURT, NOVATO CA 94949 |
22nw Fund, Lp | 10 percent owner | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Joseph F. Lawler | director, 10 percent owner | 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734 |
Areta Kupchyk | director | C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
22nw, Lp | 10 percent owner, other: See Explanation of Response | 590 1ST AVE S, UNIT C1, SEATTLE WA 98104 |
From GuruFocus
By Business Wire • 11-14-2023
By Business Wire Business Wire • 05-24-2022
By Business Wire Business Wire • 11-01-2022
By Business Wire • 08-30-2023
By Business Wire Business Wire • 08-23-2022
By Business Wire Business Wire • 02-10-2023
By Business Wire Business Wire • 07-05-2022
By Business Wire Business Wire • 01-09-2023
By Business Wire Business Wire • 01-03-2022
By Business Wire • 09-25-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.